Delta sleep-inducing peptide exhibits anticonvulsant/antiepileptic and neuromodulatory activities. In vivo, this peptide decreases the incidence, severity, and duration of metaphit-induced seizures. Delta sleep-inducing peptide potentiates GABA currents and inhibits potentiation of NMDA currents in vivo. Additionally, this peptide exhibits hypoglycemia-like properties in other animal models, inhibiting non-enzymatic glycosylation of hemoglobin and decreasing protein oxidation. In myoleukemia cells, delta sleep-inducing peptide decreases expression of HSP70.